Tássia Sell Ferreira

Tássia Sell Ferreira

Auto-generated profile, based on publicly available information

Tássia Sell Ferreira

Department of Veterinary Medicine, School of Medicine and Life Sciences Pontifical Catholic University of Paraná Curitiba PR Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 February 2025 in Veterinary Dermatology
Verified
Journal Article
Closed access
TFTássia Sell Ferreira
Tássia Sell Ferreira
WVWendy Roldán Villalobos
Wendy Roldán Villalobos
VGVANESSA CUNNINGHAM GMYTERCO
VANESSA CUNNINGHAM GMYTERCO
DFDiogo Simões Fonseca
Diogo Simões Fonseca
MFMarconi Rodrigues de Farias
Marconi Rodrigues de Farias

5 March 2025 in Veterinary Dermatology
Verified
Journal Article
Open access
WVWendie Roldan Villalobos
Wendie Roldan Villalobos
TFTássia Ferreira
Tássia Ferreira
FBFernanda Borek
Fernanda Borek
DSDomenico Santoro
Domenico Santoro
LFLluis Ferrer
Lluis Ferrer
MFMarconi Rodrigues de Farias
Marconi Rodrigues de Farias
Background: Canine atopic dermatitis (cAD) is a chronic, inflammatory, multifactorial and pruritic disease. The presence of skin barrier impairment (e.g. filaggrin alterations), along with abnormal immune responses, can negatively impact cutaneous barrier function.Objectives: To evaluate the filaggrin 2 (FLG2) expression in atopic dogs before and after the administration of oclacitinib maleate.Animals: Sixteen privately owned dogs with a diagnosis of cAD and 10 healthy control dogs.Materials and Methods: Oclacitinib maleate monotherapy at 0.5 mg/kg, orally, twice‐daily for the first 14 days and once‐daily for 16 additional days, was administered to the atopic dogs. Skin biopsies from lesional and nonlesional skin were obtained from atopic dogs on Day(D)0 and D30 and from the same anatomical locations from the control group on D0. Immunohistochemical investigation was performed using a primary custom‐made anti‐canine‐filaggrin 2 polyclonal antibody. Immunolabelled slides were scanned and FLG2 expression was measured. Data were analysed and a p‐value ≤0.05 was considered statistically significant.Results: There was a higher FLG2 expression in control skin when compared with atopic skin (lesional and nonlesional) on D0 (p = 0.033). FLG2 expression comparison between control and D30 (nonlesional) did not show a significant difference (p = 0.509). A significant increase in FLG2 expression in atopic nonlesional skin on D30 compared with nonlesional skin on D0 was also observed (p = 0.014).Conclusions and Clinical Relevance: Oclacitinib maleate could have a positive impact on cutaneous barrier structure, improving FLG2 expression by decreasing inflammation and cutaneous trauma.

29 October 2026 in Veterinary Dermatology
Verified
Journal Article
Open access
CBCristiane Bazaga Botelho
Cristiane Bazaga Botelho
TFTássia Sell Ferreira
Tássia Sell Ferreira
VGVANESSA CUNNINGHAM GMYTERCO
VANESSA CUNNINGHAM GMYTERCO
CACaroline Alves
Caroline Alves
TNTim Nuttall
Tim Nuttall
JFJúlio Israel Fernandes
Júlio Israel Fernandes
Five dogs with head tilt, ataxia, incoordination or deafness without a history of otitis externa (OE) were diagnosed with otitis media by computed tomography (CT) or magnetic resonance imaging (MRI). Otoendoscopy showed possible tympanic membrane retraction with opaque, fibrotic membranes and advanced imaging showed middle ear involvement. The clinical significance requires further investigation.